Back to Journals » Neuropsychiatric Disease and Treatment » Volume 16

Ketamine in Bipolar Disorder: A Review

Authors Wilkowska A, Szałach Ł, Cubała WJ

Received 17 September 2020

Accepted for publication 10 October 2020

Published 12 November 2020 Volume 2020:16 Pages 2707—2717


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Roger Pinder

Alina Wilkowska, Łukasz Szałach, Wiesław J Cubała

Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland

Correspondence: Alina Wilkowska
Department of Psychiatry, Faculty of Medicine, Medical University of Gdańsk, Dębinki 7 Str, Gdańsk 80-211, Poland
Tel + 48 58 349 26 50
Fax + 48 349 27 48

Abstract: Bipolar disorder (BD) is a psychiatric illness associated with high morbidity, mortality and suicide rate. It has neuroprogressive course and a high rate of treatment resistance. Hence, there is an unquestionable need for new BD treatment strategies. Ketamine appears to have rapid antidepressive and antisuicidal effects. Since most of the available studies concern unipolar depression, here we present a novel insight arguing that ketamine might be a promising treatment for bipolar disorder.

Keywords: ketamine, bipolar disorder, staging, neuroprogression, treatment resistance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]